Dermata Therapeutics (DRMA) Q3 2024 earnings summary

Executive summary

• Focused on developing DMT310 (in Phase 3 for moderate-to-severe acne) and DMT410 (targeting topical delivery of botulinum toxin for hyperhidrosis and aesthetics), with DMT310 nearing completion of enrollment and topline results expected in Q1 2025.

• No product revenue to date; operations funded primarily through equity and debt offerings, raising $68.8 million since inception and $7.8 million in gross proceeds during 2024.

• Net loss of $3.2 million for Q3 2024 and $9.1 million for the nine months ended September 30, 2024; accumulated deficit of $62.5 million.

• Cash and cash equivalents of $6.1 million as of September 30, 2024, expected to fund operations into Q2 2025.

• Continued partnership discussions for DMT410, with potential applications in hyperhidrosis, acne, and facial aesthetics.

Financial highlights

• Q3 2024 research and development expenses rose to $2.4 million, up from $0.9 million in Q3 2023, mainly due to increased clinical trial costs for DMT310.

• General and administrative expenses decreased to $0.8 million for Q3 2024, primarily from lower insurance costs.

• Net loss per share for Q3 2024 was $(2.04), compared to $(8.09) in Q3 2023, reflecting a higher share count.

• Cash used in operations was $8.2 million for the nine months ended September 30, 2024; cash provided by financing activities was $7.0 million.

• Cash and cash equivalents were $6.1 million as of September 30, 2024, down from $7.4 million at December 31, 2023.

Outlook and guidance

• Cash runway expected into Q2 2025; additional capital will be needed to complete Phase 3 studies and continue operations.

• Topline results from the first Phase 3 DMT310 trial (STAR-1) expected in Q1 2025.

• Plans to seek additional financing through equity, debt, or strategic transactions.